Your browser doesn't support javascript.
loading
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Liu, Hu; Cheng, Ying; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Ye, Changsheng; Dong, Fangli; Wu, Shuchao; Zhu, Xiaoyu; Xu, Binghe.
Afiliação
  • Ma F; Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yan M; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Li W; Department of Oncology, The First Hospital of Jilin University, Changchun, China.
  • Ouyang Q; Breast Internal Medicine Department, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Tong Z; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • Teng Y; Department of Breast Internal Medicine, The First Hospital of China Medical University, Shenyang, China.
  • Wang Y; Breast Surgery, Shandong Cancer Hospital and Institute, Jinan, China.
  • Wang S; Department of Internal Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Geng C; Breast Center, The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, China.
  • Luo T; Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Zhong J; Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Zhang Q; Ward One of Mammary Department, Harbin Medical University Cancer Hospital, Harbin, China.
  • Liu Q; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zeng X; Breast Cancer Center, Affiliated Cancer Hospital of Chongqing University, Chongqing, China.
  • Sun T; Breast Internal Medicine Department, Liaoning Cancer Hospital & Institute, Shenyang, China.
  • Mo Q; Breast Surgery, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China.
  • Liu H; Department of Medical Oncology, The First Affiliated Hospital of USTC West District, Hefei, China.
  • Cheng Y; Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
  • Cheng J; Oncology Center Breast Department, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
  • Wang X; Breast Medicine, Zhejiang Cancer Hospital, Hangzhou, China.
  • Nie J; Breast Surgery, Yunnan Cancer Hospital, Kunming, China.
  • Yang J; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Wu X; Department of Breast Oncology, Hubei Cancer Hospital, Wuhan, China.
  • Wang X; Department of Medical Oncology, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Li H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Ye C; Department of Breast, Southern Medical University Nanfang Hospital, Guangzhou, China.
  • Dong F; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
  • Wu S; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
  • Zhu X; Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
  • Xu B; Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China xubinghe@medmail.com.cn.
BMJ ; 383: e076065, 2023 10 31.
Article em En | MEDLINE | ID: mdl-37907210
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans / Middle aged Idioma: En Revista: BMJ Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans / Middle aged Idioma: En Revista: BMJ Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China